Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07602907 | Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study | recruiting | Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07757763 | Slow Jogging for Breast Cancer Survivors(SJBC) | recruiting | N/A | 104 | Mackay Memorial HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05111561 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05694559 | Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics | recruiting | N/A | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05893966 | Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer(BOOST-HER2) | recruiting | — | 400 | Samsung Medical CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06092892 | IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases | recruiting | Phase 2 | 45 | Alice ChungOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06127797 | Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue | recruiting | — | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT06930859 | Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia(ELEGANCE) | recruiting | — | 2,766 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07044310 | 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss | recruiting | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07304934 | A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer(PRO-TuFEst-LN) | recruiting | — | 400 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07482384 | Supporting Health Including Endocrine Treatment for Long Duration(SHIELD) | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | recruiting | N/A | 126 | City of Hope Medical CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06638307 | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | recruiting | Phase 1 | 240 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07140172 | Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery(OPBC-10/ NOAX) | recruiting | N/A | 1,060 | University Hospital, Basel, SwitzerlandOTHER | 11 | Aug 7, 2026 | clinicaltrials |
| NCT07242352 | Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC(ADAPTela) | recruiting | Phase 3 | 1,520 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02102165 | AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.(AURORA) | recruiting | N/A | 1,000 | Jules Bordet InstituteOTHER | 10 | Aug 6, 2026 | clinicaltrials |
| NCT05232916 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects(FLAMINGO-01) | recruiting | Phase 3 | 2,250 | Greenwich LifeSciences, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT06129747 | Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast | recruiting | Phase 2 | 55 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06176261 | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | recruiting | Phase 2 | 58 | Nancy Lin, MDOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06586047 | Breast Cancer PSMA PET | recruiting | Early Phase 1 | 30 | Ahmad ShariftabriziOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07512271 | Generative AI Patient Education Module for Breast Oncology | recruiting | N/A | 35 | University of California, San FranciscoOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04794075 | Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer(ETAPH) | recruiting | N/A | 300 | Centre Hospitalier Emile RouxOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 34 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05507879 | TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer | recruiting | — | 200 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05792150 | PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS(PROOFS) | recruiting | — | 1,470 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | recruiting | Phase 3 | 1,295 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 5, 2026 | clinicaltrials |
| NCT06106477 | Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer | recruiting | N/A | 20 | Medical College of WisconsinOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06469606 | Study on Female Patients' Mammographic Texture Features(COMPRESS) | recruiting | N/A | 200 | Tampere University HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06658912 | Planning Grant for TOPS for Breast Cancer Survivors | recruiting | N/A | 25 | Duke UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07281833 | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment(CAPIcorn) | recruiting | Phase 3 | 250 | Women's Cancer Study Group GmbHOTHER | 3 | Aug 5, 2026 | clinicaltrials |
| NCT07580105 | Clinical Study to Assess the Safety and Performance of Kenko Breast AI+ Medical Device as an Aid to Breast Cancer Diagnosis in Adult Women | recruiting | — | 200 | Kenko Imalytics S.L.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT05621564 | Pre-operative Therapy in Breast Cancer | recruiting | — | 6,032 | RenJi HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06123286 | Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms | recruiting | Early Phase 1 | 30 | Philip ChangOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06195306 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06748222 | E-Mindfulness Approaches for Living After Breast Cancer(HEAL-ABC) | recruiting | Phase 3 | 402 | NRG OncologyOTHER | 2 | Aug 4, 2026 | clinicaltrials |
| NCT07017673 | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | recruiting | Phase 2 | 34 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07078604 | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07739485 | Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study(GBCF003) | recruiting | Phase 1 / Phase 2 | 30 | Liu ShuOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07739511 | Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study(GBCF002) | recruiting | Phase 1 / Phase 2 | 30 | Liu ShuOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743827 | Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors | recruiting | N/A | 90 | Alexandria UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743944 | A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.(VERITAS) | recruiting | — | 2,000 | AstraZenecaINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04360330 | SABER Study for Selected Early Stage Breast Cancer(SABER) | recruiting | N/A | 18 | University of MiamiOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06081244 | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)(ADAPT-TN-III) | recruiting | Phase 3 | 348 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06922708 | Implementing Polygenic Risk Scores for Breast Cancer Prevention: a Feasibility Study(MIG) | recruiting | N/A | 100 | Catholic University of the Sacred HeartOTHER | 1 | Aug 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 11, 2026source: clinicaltrials